PIKfyve-Specific Inhibitors Restrict Replication of Multiple Coronaviruses In Vitro but Not in a Murine Model of COVID-19

Scientists showed that, while Apilimod and other PIKfyve inhibitors had potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsened disease in a COVID-19 murine model when given prophylactically or therapeutically.